The controversial healthcare conglomerate is accused of systematically diagnosing patients with as many conditions as ...

Medtronic Diabetes has expanded U.S. pharmacy formulary access for its MiniMed 780F insulin pump through agreements with ...

Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...

Type 1.5 diabetes affects up to 12% of adults but gets misdiagnosed as type 2. Find out if your symptoms match this hidden ...

Federal health officials have laid out a new plan to expand access to GLP-1 drugs for weight loss and diabetes, signaling a ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...

Ollin Biosciences Inc. is gearing up for global phase III trials this year after disclosing favorable top-line results from its randomized, head-to-head phase Ib Jade study comparing OLN-324, a ...

Panelists discuss how clinicians manage suboptimal responders by focusing on stability rather than complete dryness, using ...

As California ends Medicaid coverage for GLP-1 weight loss drugs like Wegovy and Zepbound, experts say the state's advice to ...

Medicare is changing in 2026. Learn about the new Part D drug cap, insulin price locks, Part B shifts, the WISeR pilot ...

In the Phase Ib JADE trial, OLN324 demonstrated both faster and greater retinal drying versus Vabysmo in patients with DME, ...

GLP-1 meds are are highly effective at treating diabetes, obesity and other conditions. But when people stop using them, the ...